ProQR Therapeutics (PRQR) Non Operating Income (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Non Operating Income for 14 consecutive years, with $241246.3 the latest figure, recorded in Q1 2026.

• Quarterly Non Operating Income rose 141.73% year-over-year to $241246.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200280.0 (down 81.7% YoY) and the FY2021 annual result came in at $3.2 million, up 175.05% from the prior year.
• Non Operating Income slipped to $241246.3 in Q1 2026 per PRQR's latest filing, from $318627.2 in the prior quarter.
• Over the last five years, Non Operating Income for PRQR reached as high as $1.4 million in Q1 2022 and fell as low as -$619047.1 in Q1 2023.
• A 5-year average of $433823.2 and a median of $533700.6 in 2024 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income surged 329.69% — and 2025, when it tumbled 204.1%.
• Year by year, Non Operating Income stood at $681634.6 in 2022, then sank by 39.4% to $413077.4 in 2023, then gained by 29.2% to $533700.6 in 2024, then plunged by 40.3% to $318627.2 in 2025, then dropped by 24.29% to $241246.3 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $241246.3, $318627.2, and $218487.2 for Q1 2026, Q3 2025, and Q2 2025 respectively.